Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 220 E First St BETHLEHEM PA 18015 |
Tel: | N/A |
Website: | https://www.orasure.com |
IR: | See website |
Key People | ||
Carrie Eglinton Manner President, Chief Executive Officer, Director | Kenneth J. Mcgrath Chief Financial Officer | Kathleen Gallagher Weber Chief Product Officer |
Business Overview |
OraSure Technologies, Inc. provides point-of-care and home diagnostic tests, sample management solutions, and microbiome laboratory and analytical services. The Company's product portfolio is divided into diagnostics products and sample management solutions. Its business consists of the development, manufacture, marketing and sale of diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Its diagnostic products include tests for diseases including COVID-19, HIV and Hepatitis C that are performed on a rapid basis at the point of care, and tests for drugs of abuse that are processed in a laboratory. Its business also includes molecular sample management solutions and services that are used by clinical laboratories, direct-to-consumer laboratories, researchers, pharmaceutical companies, and animal health service and product providers. |
Financial Overview |
For the fiscal year ended 31 December 2023, OraSure Technologies, Inc. revenues increased 5% to $405.5M. Net income totaled $53.7M vs. loss of $17.1M. Revenues reflect United States segment increase of 3% to $361.7M, Other Regions segment increase of 39% to $35.7M. Net Income reflects Other income - Balancing value increase from $4.9M to $23.7M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.24 to $0.73. |
Employees: | 638 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $133.46M as of Dec 31, 2023 |
Annual revenue (TTM): | $405.47M as of Dec 31, 2023 |
EBITDA (TTM): | $75.11M as of Dec 31, 2023 |
Net annual income (TTM): | $53.66M as of Dec 31, 2023 |
Free cash flow (TTM): | $131.28M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 76,509,975 as of Mar 22, 2024 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |